Article
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2005
Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam C-M, Gustavsson B, Bergh J
Abstract excerpt
BACKGROUND: TP53 has been described as a prognostic factor in many malignancies, including breast cancer. Whether it also might be a predictive factor with reference to chemo- and endocrine therapy is more controversial. PATIENTS AND METHODS: We investigated relapse-free (RFS), breast cancer-corrected (BCCS) and overall survival (OS) related to TP53 status in node-positive breast cancer patients that had received...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Cisplatin
- Cohort Studies
- Female
- Fluorouracil
- Gene Expression Regulation, Neoplastic
- Genes, p53
- Genetic Markers